Scarica l'app Stockscreener
26.49
1.07%
0.28
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
Geode Capital Management LLC Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Wellington Management Group LLP Decreases Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma's SWOT analysis: innovative pipeline drives stock potential - Investing.com
KRAS Inhibitors Market Top Companies StudyAmgen, Boehringer - openPR
HC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Holdings Lifted by Barclays PLC - MarketBeat
BridgeBio's SWOT analysis: genetic disease specialist's stock poised for growth By Investing.com - Investing.com South Africa
BridgeBio's SWOT analysis: genetic disease specialist's stock poised for growth - Investing.com Australia
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is Exome Asset Management LLC's 3rd Largest Position - MarketBeat
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP - BioCentury
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Yahoo Finance
Learn to Evaluate (BBIO) using the Charts - Stock Traders Daily
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Frazier Life Sciences Management L.P. Buys 127,853 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market: Size, Share, - openPR
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 8.4%Should You Buy? - MarketBeat
Polar Asset Management Partners Inc. Buys Shares of 50,500 BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Janus Henderson Group PLC Increases Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Melqart Asset Management UK Ltd Grows Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
HighVista Strategies LLC Acquires 24,482 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Unnatural Products Announces BridgeBio Exercises Option to - GlobeNewswire
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for - The Bakersfield Californian
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology - Yahoo Finance
Erste Asset Management GmbH Invests $3.50 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma (BBIO) Stock Surges on FDA Approval of Lead Treatment - Nasdaq
BridgeBio Pharma (FRA:2CL) Price-to-Operating-Cash-Flow : (As of Dec. 01, 2024) - GuruFocus.com
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease - AOL
The week in pharma: action, reaction and insight – week to November 29 - The Pharma Letter
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More - Yahoo Finance
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug - MSN
Intech Investment Management LLC Makes New Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Soars After Drug Gets Nod in Rare Heart Condition - MSN
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug - MSN
HC Wainwright Has Optimistic Outlook of BBIO FY2024 Earnings - MarketBeat
Research Analysts Offer Predictions for BBIO FY2024 Earnings - MarketBeat
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug - MSN
BridgeBio Pharma (FRA:2CL) Total Liabilities : €1,696.9 Mil (As of Sep. 2024) - GuruFocus.com
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby - Marketscreener.com
BridgeBio: Shares Surge as Attruby Gains FDA Approval; Slightly Raising Our Fair Value Estimate - Morningstar
BridgeBio's Attruby (Acoramidis) Approval Could Pave Way for Long-Term Profitability - Morningstar
What is Leerink Partnrs' Estimate for BBIO FY2027 Earnings? - MarketBeat
BridgeBio price target raised to $45 from $42 at BofA - Yahoo Finance
Eagle Asset Management Inc. Lowers Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Algert Global LLC Has $3.47 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Massachusetts Financial Services Co. MA Grows Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds - MSN
BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer - MSN
FDA approves BridgeBio’s Attruby for ATTR-CM treatment - Indian Pharma Post
BridgeBio Pharma Receive FDA Nod for Attruby - Diagnostic and Interventional Cardiology
BridgeBio’s Attruby Could Benefit From ‘Best-Case’ Label, Lower Price - News & Insights
Health Care Up Amid Cyclical Bias -- Health Care Roundup - Marketscreener.com
Bridgebio, with FDA approval, faces Pfizer in ATTR - BioWorld Online
Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race - FirstWord Pharma
BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug - Investor's Business Daily
Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY™ (acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis - Yahoo Finance
Gold Down Over 3%; Rigetti Computing Shares Spike Higher - Benzinga
FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug - MedCity News
BridgeBio's SWOT analysis: genetic disease fighter's stock faces pivotal moment - Investing.com
BridgeBio stock retains Overweight; Piper Sandler highlights competitive pricing for Attruby - Investing.com
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):